DSIP (Delta Sleep-Inducing Peptide)

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated from the blood of rabbits during studies of sleep physiology in the 1970s. It has since been studied, with mixed and sometimes contradictory results, for its proposed ability to promote delta-wave sleep, along with anti-stress, analgesic, and antioxidant properties described in various animal and small human studies. Despite decades of intermittent research, its exact physiological role and mechanism remain incompletely understood, and later studies have not consistently replicated its original sleep-promoting effects. It is not approved for medical use and is available only as a research compound. Reported benefits include studied for potential support of delta-wave (deep) sleep in some research, explored for stress-modulating and anti-anxiety properties, investigated for analgesic effects in preclinical studies.

Reported ranges run 100-300 mcg. A low protocol is 100 mcg before bedtime, and a high protocol is 300 mcg before bedtime. This is reference information, not a dosing recommendation.

Reported to be short, generally cited at under an hour in early pharmacokinetic studies, though its downstream effects on sleep architecture may extend well beyond its detectable presence.. That is what sets the dosing frequency, and it is why the timing guidance is ~30 min before bed.

Subcutaneous: into fat, under the skin. Administered by subcutaneous injection in research contexts.

2-4 weeks on, followed by 2-4 weeks off. Intermittent or as-needed use is more commonly discussed than continuous daily use, given inconsistent evidence for sustained effect.

Reported side effects include inconsistent effects reported across studies, including lack of effect in some trials, injection site irritation with subcutaneous use, possible vivid dreaming or altered sleep architecture reported anecdotally, limited modern controlled human safety data. Evidence level for this compound is emerging research.